Retraction to: Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis (Tumor Biol., (2014), 35, (6687-6693), DOI 10.1007/s13277-014-1885-1);Relationships between PTEN gene mutations and prognosis in glioma: A meta-analysis

Tumor Biology

Volumn 35, Issue 7, 2014, Pages 6687-6693

  Xiao, Wei Zhong ^a   Han, Dong Hua ^a   Wang, Fei ^b   Wang, Yong Qian ^c   Zhu, You Hou ^b   Wu, Yi Fang ^b   Liu, Ning Tao ^b   Sun, Ji Yong ^d  

^a FUDAN UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

^c SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Gene mutations; Glioma; Meta analysis; PTEN

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; CANCER PROGNOSIS; GENE MUTATION; GENETIC ASSOCIATION; GLIOMA; HUMAN; ITALY; MALAYSIA; OVERALL SURVIVAL; PRIORITY JOURNAL; SWEDEN;

BRAIN NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; GLIOMA; HUMANS; MUTATION; PROGNOSIS; PTEN PHOSPHOHYDROLASE;

EID: 84904963241     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3715-5     Document Type: Erratum

References (38)

1. Goodenberger ML, Jenkins RB. Genetics of adult glioma. Cancer Genet. 2012;205(12):613-21.
2. Sizoo EM, Braam L, Postma TJ, Pasman HR, Heimans JJ, Klein M, et al. Symptoms and problems in the end-of-life phase of high-grade glioma patients. Neuro Oncol. 2010;12(11):1162-6.
3. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 2013;15 Suppl 2:ii1-56.
4. Melin B. Genetic causes of glioma: New leads in the labyrinth. Curr Opin Oncol. 2011;23(6):643-7.
5. Benson VS, Pirie K, Green J, Casabonne D, Beral V. Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. Br J Cancer. 2008;99(1):185-90.
6. Little MP, Rajaraman P, Curtis RE, Devesa SS, Inskip PD, Check DP, et al. Mobile phone use and glioma risk: Comparison of epidemiological study results with incidence trends in the United States. BMJ. 2012;344:e1147.
7. Baglietto L, Giles GG, English DR, Karahalios A, Hopper JL, Severi G. Alcohol consumption and risk of glioblastoma; evidence from the Melbourne Collaborative Cohort Study. Int J Cancer. 2011;128(8):1929-34.
8. Chen C, Xu T, Chen J, Zhou J, Yan Y, Lu Y, et al. Allergy and risk of glioma: a meta-analysis. Eur J Neurol. 2011;18(3):387-95.
9. Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 2009;100(12):2235-41.
10. Liu Y, Shete S, Hosking F, Robertson L, Houlston R, Bondy M. Genetic advances in glioma: Susceptibility genes and networks. Curr Opin Genet Dev. 2010;20(3):239-44.
11. Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, Rouhanifard SH, et al. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev. 2009;23(11):1327-37.
12. Dey N, Crosswell HE, De P, Parsons R, Peng Q, Su JD, et al. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res. 2008;68(6):1862-71. (Pubitemid 351416572)
13. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell. 2008;133(3):403-14. (Pubitemid 351622014)
14. Chu EC, Tarnawski AS. PTEN regulatory functions in tumor suppression and cell biology. Med Sci Monit. 2004;10(10):RA235-41. (Pubitemid 39424480)
15. Marsit CJ, Zheng S, Aldape K, Hinds PW, Nelson HH, Wiencke JK, et al. PTEN expression in non-small-cell lung cancer: Evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol. 2005;36(7):768-76. (Pubitemid 41112032)
16. Alexiou GA, Voulgaris S. The role of the PTEN gene in malignant gliomas. Neurol Neurochir Pol. 2010;44(1):80-6.
17. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275(5308):1943-7. (Pubitemid 27148818)
18. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008;68(15):6084-91.
19. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19(5):575-86.
20. Hou P, Ji M, Xing M. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer. 2008;113(9):2440-7.
21. Aguissa-Toure AH, Li G. Genetic alterations of PTEN in human melanoma. Cell Mol Life Sci. 2012;69(9):1475-91.
22. Kwon CH, Zhao D, Chen J, Alcantara S, Li Y, Burns DK, et al. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res. 2008;68(9):3286-94.
23. Idbaih A, Dalmasso C, Kouwenhoven M, Jeuken J, Carpentier C, Gorlia T, et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. J Neurooncol. 2011;103(2):221-30.
24. Abdullah JM, Farizan A, Asmarina K, Zainuddin N, Ghazali MM, Jaafar H, et al. Association of loss of heterozygosity and PTEN gene abnormalities with paraclinical, clinical modalities and survival time of glioma patients in Malaysia. Asian J Surg. 2006;29(4):274-82. (Pubitemid 44701988)
25. Jansen M, Yip S, Louis DN. Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol. 2010;9(7):717-26.
26. D'Urso OF, D'Urso PI, Marsigliante S, Storelli C, Luzi G, Gianfreda CD, et al. Correlative analysis of gene expression profile and prognosis in patients with gliomatosis cerebri. Cancer. 2009;115(16):3749-57.
27. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93(16):1246-56. (Pubitemid 32816199)
28. Yang Y, Shao N, Luo G, Li L, Zheng L, Nilsson-Ehle P, et al. Mutations of PTEN gene in gliomas correlate to tumor differentiation and short-term survival rate. Anticancer Res. 2010;30(3):981-5.
29. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603-5.
30. Zintzaras E, Ioannidis JP. HEGESMA: Genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005;21(18):3672-3. (Pubitemid 41264106)
31. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28(2):123-37.
32. Zhou L, Yao F, Luan H, Wang Y, Dong X, Zhou W, et al. Three novel functional polymorphisms in the promoter of FGFR2 gene and breast cancer risk: a HuGE review and meta-analysis. Breast Cancer Res Treat. 2012;136(3):885-97.
33. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676-80. (Pubitemid 43209069)
34. James CD, Galanis E, Frederick L, Kimmel DW, Cunningham JM, Atherton-Skaff PJ, et al. Tumor suppressor gene alterations in malignant gliomas: Histopathological associations and prognostic evaluation. Int J Oncol. 1999;15(3):547-53.
35. Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol. 2001;159(1):359-67. (Pubitemid 33704221)
36. Georgescu MM. PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer. 2010;1(12):1170-7.
37. Abounader R. Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy. Expert Rev Anticancer Ther. 2009;9(2):235-45.
38. Dasari VR, Kaur K, Velpula KK, Gujrati M, Fassett D, Klopfenstein JD, et al. Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway. PLoS One. 2010;5(4):e10350.